CN
Tides CDMO Services

With four major R&D platforms including peptides, oligonucleotides, high-performance liquid chromatography, and Tides analysis, the Porton Tides CDMO Services Platform is committed to providing integrated CMC solutions for global customers, covering all types of new drugs from pre-clinical to commercial.

Contact Us

    100+

    Customers

    30+

    Projects (IND/P1/P2/P3/NDA)

    150+

    Scientists

Our Services

    Peptides

    Linear Peptides (<50 aa)

    Cyclic Peptides (<50 aa)

    Peptide Modifications

    Key RSMs and Intermediates

    Oligonucleotides

    ASO, siRNA

    PMO

    Aptamer

    sgRNA

    Oligo Modifications

    Drug Delivery Materials

    Ionizable Lipids/Cationic Lipids

    Polymers for Drug Delivery

    Complex/Conjugate Polysaccharides

    Other Lipids

Peptides

Linear Peptides (<50 aa)

Cyclic Peptides (<50 aa)

Peptide Modifications

Key RSMs and Intermediates

Molecular Type
  • Linear Peptides (<50 aa)
  • Cyclic Peptides (<50 aa)
  • Arginine-rich Peptides
  • Stapled Peptides
  • Peptide Modifications: PEG, lipidation, N-methylation, etc.
  • Key RSMs and Intermediates
  • ADC Drug-Linker and PDC (OEB 5)
Technology
  • Solid/Liquid/Hybrid Strategies Synthetic Solutions
  • Combinate Downstream Technologies with Rp-prep-HPLC, Ionic Exchange, and TFF Technology
  • Pre-formulation Development
  • Comprehensive Analysis and Quality Research
Service Scope
  • mg-g Scale Sample Preparation for Pre-clinical Studies
  • Process Development and Scale-up Mfg. (non-GMP and GMP)
  • Formulation Development and GMP Manufacturing
  • Analytical Method Development, Validation, and Stability Study
  • IND/NDA CMC Dossier
Service Mode
  • Full Time Employee (FTE)
  • Fee for Service (FFS)
Oligonucleotides

ASO, siRNA

PMO

Aptamer

sgRNA

Oligo Modifications

Molecular Type
  • 16~100 mer Oligonucleotides and Derivatives
  • Modified Nucleotides
  • Oligonucleotide Conjugates
  • Custom Monomer
  • Custom Galnac Derivatives
Technology
  • Solid Phase Oligonucleotide Synthesis Technology Platform
  • Ion Exchange, Ultrafiltration, Freeze-drying, and Other Purification and Post-processing Technologies
  • Nucleic Acid Modification and Routine Injection Preparation Research and Development Capability (Including LNP)
  • Comprehensive Analysis and Quality Research
Service Scope
  • mg to g Scale Sample Preparation for Pre-clinical Studies
  • Process Development and Scale-up Manufacturing (non-GMP and GMP)
  • Formulation Development and GMP Manufacturing
  • Analytical Method Development, Validation, and Stability Study
  • IND/NDA CMC Dossier
Service Mode
  • FTE (Full-Time Equivalent)
  • FFS (Fee for Service)
Drug Delivery Materials

Ionizable Lipids/Cationic Lipids

Polymers for Drug Delivery

Complex/Conjugate Polysaccharides

Other Lipids

Molecular Type
  • Polymer-drug Conjugates, Dendrimers, Polypeptides
  • Cationic/Ionizable Lipids, Peg-lipid, Phospholipids
  • GalNAc Derivatives, Modified Monosaccharides, Synthetic Oligo[poly]saccharides
Technology
  • Solid Phase and Liquid Phase Synthesis Technology Platform
  • Combinate Downstream Technologies with prep-HPLC and Rp-prep-HPLC, Ionic Exchange, and TFF Technology
  • Formulations Development and Manufacturing
  • Comprehensive Analysis, Inspection and Quality Research
Service Scope
  • mg-g Scale Sample Preparation for Pre-clinical Studies
  • Process Development and Scale-up Mfg. (non-GMP & GMP)
  • Analytical Method Development, Validation, and Stability Study
  • IND/NDA CMC Dossier
Service Mode
  • FTE (Full-Time Equivalent)
  • FFS (Fee for Service)
  • Become part of Porton' s community to access personalized insights and resources.
    Submit
    By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

    ⓒ 2024 PORTON Legal Notices | Porton Privacy

    This website contains information on products which are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your countries. Please be aware that we do not take any responsibity for accessing suchinlomaon which may not compy wih anylegal process,regulaion,registraton or usage in the counry of your origin.

    Become part of Porton' s community to access personalized insights and resources.
    Submit
    By clicking "Submit" you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

    Copyright © PORTON 2024. All Rights Reserved.

    Legal Notices Porton Privacy
    US: (609) 860-1300
    CN: (86) 23-8608-3200